<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94204">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02062255</url>
  </required_header>
  <id_info>
    <org_study_id>CTRC 13-0041</org_study_id>
    <secondary_id>HSC20130426H</secondary_id>
    <nct_id>NCT02062255</nct_id>
  </id_info>
  <brief_title>Impact of COX2 on Sera Biomarkers From Obese Subjects</brief_title>
  <official_title>A Phase 0, Investigator Initiated Study, Evaluating the Impact of COX2 Inhibition on Human Sera Biomarkers From Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity promotes worse outcome for post-menopausal breast cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Biomarker levels</measure>
    <time_frame>29 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood levels of Prostaglandin E2, aromatase, pro-inflammatory cytokines, steroids, and lipids will be measured pre and post treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>29 Days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Correlation for body mass index impact on response to COX2 inhibition.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Breast Cancer Survivors</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Twenty eight enteric coated 81mg Aspirin tablets will be dispensed for daily oral dosing, to be taken with a meal at the same time of day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omega-3 Free Fatty Acids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three hundred thirty-six gelatin coated  450 mg capsules containing approximately 180 mg of EPA and 135 mg of DHA will be dispensed. Patients are to take 12 capsules daily with meals, either once daily (12 capsules with one meal) or divided twice daily (e.g., six with breakfast and six with dinner).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin &amp; Omega-3 FFAs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin (81 mg po daily) to be taken simultaneously with Omega-3 Free Fatty Acids (1500mg of docosahexaoic acid (DHA) and 2500mg eicosapentanoic acid (EPA) given daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_label>Aspirin &amp; Omega-3 FFAs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega 3 FFA</intervention_name>
    <arm_group_label>Omega-3 Free Fatty Acids</arm_group_label>
    <arm_group_label>Aspirin &amp; Omega-3 FFAs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Post-menopausal as confirmed by medical history

          -  Ability to understand the purposes and risks of the study and has signed a written
             informed consent form approved by the investigator's IRB/Ethics Committee

        Exclusion Criteria:

          -  Evidence of active cancer (patients with a prior history of malignancy are encouraged
             to participate, but due to cytokine levels associated with malignancy there must be
             no evidence of disease)

          -  Cachexia

          -  Active systemic illness (infection including viral illnesses such as Hepatitis and
             HIV)

          -  Chronic use of aspirin of omega-3 free fatty acid supplementation within the last 60
             days (defined as greater than or equal to 7 consecutive days)

          -  Known hypersensitivity to aspirin and/or omega-3 fatty acids

          -  Actively receiving a physician-directed regimen of aspirin and/or receiving
             herapeutic/prophylactic anticoagulation

          -  Any aspirin or omega-3 free fatty acid supplementation within the last 14 days

          -  Subjects who are pregnant

          -  History of medical noncompliance
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Brenner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Epp Goodwin</last_name>
    <phone>210-450-5798</phone>
    <email>goodwine@uthscsa.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Therapy and Research Center at UTHSCSA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Epp Goodwin</last_name>
      <phone>210-450-5798</phone>
      <email>goodwine@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Brenner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 11, 2014</lastchanged_date>
  <firstreceived_date>December 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Andrew Brenner</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Asprin</keyword>
  <keyword>Omega-3 Free Fatty Acids</keyword>
  <keyword>Obesity</keyword>
  <keyword>COX-2 inhibitor</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
